Trial Profile
Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Reduced-antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine (Tdap) in Pregnant Thai Women
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 26 Mar 2020
Price :
$35
*
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Pharmacodynamics
- 15 Feb 2020 Results assessing Seroprevalence of Bordetella pertussis antibodies and anti-pertussis antibody response after a single dose of reduced-antigen combined diphtheria, tetanus, and acellular pertussis vaccine (Tdap) in pregnant Thai women, published in the Vaccine
- 28 Jul 2019 Status changed from active, no longer recruiting to completed.
- 06 Oct 2018 Planned End Date changed from 1 Feb 2019 to 1 Apr 2019.